ZA969290B - Stabilizing formulation for NGF. - Google Patents

Stabilizing formulation for NGF.

Info

Publication number
ZA969290B
ZA969290B ZA9609290A ZA969290A ZA969290B ZA 969290 B ZA969290 B ZA 969290B ZA 9609290 A ZA9609290 A ZA 9609290A ZA 969290 A ZA969290 A ZA 969290A ZA 969290 B ZA969290 B ZA 969290B
Authority
ZA
South Africa
Prior art keywords
ngf
stabilizing formulation
stabilizing
formulation
maturation
Prior art date
Application number
ZA9609290A
Other languages
English (en)
Inventor
Linda R De Young
Xanthe M Lam
Tue Nguyen
Michael F Powell
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24214304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA969290(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA969290B publication Critical patent/ZA969290B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9609290A 1995-11-07 1996-11-05 Stabilizing formulation for NGF. ZA969290B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55468595A 1995-11-07 1995-11-07

Publications (1)

Publication Number Publication Date
ZA969290B true ZA969290B (en) 1998-05-05

Family

ID=24214304

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9609290A ZA969290B (en) 1995-11-07 1996-11-05 Stabilizing formulation for NGF.

Country Status (18)

Country Link
EP (1) EP0862452B1 (ja)
JP (1) JP4057058B2 (ja)
KR (1) KR100497087B1 (ja)
CN (1) CN1126567C (ja)
AT (1) ATE255903T1 (ja)
AU (1) AU721112B2 (ja)
BR (1) BR9611571B1 (ja)
CA (1) CA2234231C (ja)
DE (1) DE69631063T2 (ja)
DK (1) DK0862452T3 (ja)
ES (1) ES2211991T3 (ja)
HK (1) HK1015261A1 (ja)
IL (1) IL124004A (ja)
MX (1) MX9803342A (ja)
PT (1) PT862452E (ja)
TR (1) TR199800811T2 (ja)
WO (1) WO1997017087A1 (ja)
ZA (1) ZA969290B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7214998A (en) * 1997-04-11 1998-11-11 Regents Of The University Of California, The Ngf for the prevention of demyelination in the nervous system
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
AU776823B2 (en) * 1998-07-23 2004-09-23 Ares Trading S.A. FSH and FSH variant formulations, products and methods
EP1407770B1 (en) * 2001-06-26 2013-06-05 Takeda Pharmaceutical Company Limited Tgf-beta superfamily production/secretion promoter
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
DK1610822T4 (en) 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
CA2526099C (en) 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ES2893239T3 (es) * 2015-04-21 2022-02-08 Staidson Beijing Biopharmaceuticals Co Ltd Composición de factor de crecimiento nervioso y polvo de inyección
WO2017117701A1 (zh) * 2016-01-04 2017-07-13 葡萄王生技股份有限公司 预防听力退化的活性物质、含其的组合物、及其制备方法
CN114252519B (zh) * 2020-09-23 2023-11-24 舒泰神（北京）生物制药股份有限公司 一种测定神经生长因子纯度的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor

Also Published As

Publication number Publication date
PT862452E (pt) 2004-04-30
KR100497087B1 (ko) 2005-09-09
CN1201394A (zh) 1998-12-09
KR19990067350A (ko) 1999-08-16
EP0862452A1 (en) 1998-09-09
BR9611571A (pt) 1999-03-30
ES2211991T3 (es) 2004-07-16
IL124004A (en) 2003-10-31
DE69631063D1 (de) 2004-01-22
BR9611571B1 (pt) 2009-01-13
JP4057058B2 (ja) 2008-03-05
ATE255903T1 (de) 2003-12-15
HK1015261A1 (en) 1999-10-15
DE69631063T2 (de) 2004-09-30
EP0862452B1 (en) 2003-12-10
CA2234231A1 (en) 1997-05-15
WO1997017087A1 (en) 1997-05-15
DK0862452T3 (da) 2004-04-05
MX9803342A (es) 1998-09-30
TR199800811T2 (xx) 1998-07-21
JP2002502358A (ja) 2002-01-22
AU7518696A (en) 1997-05-29
AU721112B2 (en) 2000-06-22
CA2234231C (en) 2009-04-14
CN1126567C (zh) 2003-11-05

Similar Documents

Publication Publication Date Title
ZA969290B (en) Stabilizing formulation for NGF.
IL124941A0 (en) Formulations of nerve growth factor suitable for lyophilization
AU644610B2 (en) Synergistic microbicidal combinations
AU693747B2 (en) Imidazo(4,5-c)pyridin-4-amines
AU4718496A (en) Use of aerogels in agriculture
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
AU1226092A (en) Methods and compositions for the expression of biologically active eukaryotic cytochrome p450s in bacteria
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
PH31320A (en) Fenbendazole formulations.
AU5355498A (en) 15-fluoro prostaglandins as ocular hypotensives
GR3029319T3 (en) Use of tri(n-butyl) phosphate at low pH in solutions of biologically active proteins for enhanced virucidal activity
AU4299696A (en) Use of the hepatocyte growth factor to induce proliferation and differentiation of hemopoietic cells
EP0820507B8 (en) Ndf peptides
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel
ES8705466A1 (es) Un metodo para la preparacion del factor nkbs regulador del cancer humano.
AU6449894A (en) Nutrient formulations and methods of treating malnutrition in aids